Cancer Profiling Market Size (2024 - 2029)

The cancer profiling market is anticipated to experience substantial growth, driven by the increasing incidence of cancer and heightened research funding in cancer genomics. The market's expansion is further supported by the clinical benefits of personalized treatments through cancer profiling, which have gained prominence post-pandemic. Despite a temporary decline due to pandemic-related disruptions, the market has rebounded, reflecting the growing demand for effective diagnostic solutions. However, the need for high capital investment poses a challenge to market growth.

Market Size of Cancer Profiling Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Cancer Profiling Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 10.80 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Cancer Profiling Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Cancer Profiling Market Analysis

The cancer profiling market is projected to register a CAGR of 10.8% during the forecast period.

  • The cancer profiling market has seen a significant surge due to the importance of cancer profiling in COVID-19. According to the study published in ACS publication in November 2022, COVID-19 is even more dangerous to people with comorbidities such as cancer. Thus, it is crucial to pinpoint the important human genes or biomarkers that may be used to target new prognostic and therapeutic approaches. The information provided on transcription by the next-generation sequencing technique makes this identification of cancer genes very easy. Therefore, the market has seen a slight decline in the early pandemic due to stringent lockdowns and supply chain restrictions but post-pandemic, the market has gained significant traction to reduce cancer in COVID-19 patients.
  • The factors driving the market growth include the increasing incidence of cancer and rising research and funding for cancer genomics. According to the International Agency for Research on Cancer (IARC) 2023, the global incidence of cancer is expected to reach 24.6 million by the year 2030 and 30.2 million by 2040. This high incidence rate of cancer worldwide will drive the demand for precise and effective diagnostics solutions, which will drive the growth of the studied market worldwide.
  • Furthermore, the rising clinical benefits of cancer profiling to provide personalized treatments for cancer is anticipated to drive the market growth. For instance, according to the study published in Journal of Clinical Oncology in April 2022, huge clinical benefits associated with genomic profiling to develop targeted therapies resulted in a greater demand for the assays.
  • Similarly, increasing funding for cancer research is another factor for the growth of the market. For instance, according to the National Intitute of Health in March 2023, the estimated spending on cancer research and development is USD 8,087, USD 7,635 and USD 7,632 in 2021, 2022 and 2023 respectively in the United States. Therefore, the rising investment on cancer research is anticipated to increase the adoption of cancer profiling to identify genes, proteins, or other molecules driving the market growth.
  • Thus, the studied market is expected to project lucrative growth over the forecast period owing to the factors such as rising incidence of cancer, increasing funding for cancer, among others. However, high capital investment will hinder the market growth.

Cancer Profiling Industry Segmentation

Cancer profiling scans the DNA, RNA, or protein from a patient's cancer cells to understand what molecules drive cancer growth. It starts from a specimen that may be accessed through a biopsy, surgery, or a blood sample.

The cancer profiling market is segmented by technology (immunoassays, next-generation sequencing, polymerase chain reaction, in situ hybridization, microarrays, and other technologies), cancer type (breast cancer, lung cancer, colorectal cancer, and other cancer types), biomarker type (genetic biomarkers, protein biomarkers, and other biomarker types), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (USD) for the above segments.

By Technology
Immunoassays
Next Generation Sequencing
Polymerase Chain Reaction
In Situ Hybridization
Microarrays
Other Technologies
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Other Cancer Types
By Biomarker Type
Genetic Biomarkers
Protein Biomarkers
Other Biomarker Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Cancer Profiling Market Size Summary

The cancer profiling market is experiencing robust growth, driven by the increasing incidence of cancer and the rising demand for precise diagnostic solutions. The market's expansion is further fueled by advancements in cancer genomics and the critical role of cancer profiling in developing targeted therapies, particularly highlighted during the COVID-19 pandemic. The adoption of next-generation sequencing techniques has simplified the identification of cancer-related genes, enhancing the development of prognostic and therapeutic approaches. Despite initial setbacks due to pandemic-related disruptions, the market has rebounded, supported by increased research funding and the clinical benefits of personalized cancer treatments. However, the high capital investment required for cancer profiling technologies poses a challenge to market growth.

The market is characterized by significant activity from key players and government initiatives aimed at improving cancer screening and detection. The prevalence of colorectal cancer, in particular, has spurred demand for screening tests, contributing to market growth. Strategic partnerships, acquisitions, and product launches by major companies are further propelling the market forward. North America is anticipated to hold a substantial market share, driven by the high incidence of cancer and ongoing product innovations. The competitive landscape is marked by the presence of several major players, including Illumina, QIAGEN, and NeoGenomics Laboratories, who are actively investing in cancer genomics and launching innovative profiling products to enhance their market positions.

Explore More

Cancer Profiling Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Incidence of Cancer

      2. 1.2.2 Increasing Cancer Research and Funding

    3. 1.3 Market Restraints

      1. 1.3.1 High Capital Investment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Technology

      1. 2.1.1 Immunoassays

      2. 2.1.2 Next Generation Sequencing

      3. 2.1.3 Polymerase Chain Reaction

      4. 2.1.4 In Situ Hybridization

      5. 2.1.5 Microarrays

      6. 2.1.6 Other Technologies

    2. 2.2 By Cancer Type

      1. 2.2.1 Breast Cancer

      2. 2.2.2 Lung Cancer

      3. 2.2.3 Colorectal Cancer

      4. 2.2.4 Other Cancer Types

    3. 2.3 By Biomarker Type

      1. 2.3.1 Genetic Biomarkers

      2. 2.3.2 Protein Biomarkers

      3. 2.3.3 Other Biomarker Types

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East & Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East & Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Cancer Profiling Market Size FAQs

The Global Cancer Profiling Market is projected to register a CAGR of 10.80% during the forecast period (2024-2029)

Illumina, Inc, QIAGEN, Sysmex Corporation, NeoGenomics Laboratories and HTG Molecular Diagnostics, Inc. are the major companies operating in the Global Cancer Profiling Market.

Cancer Profiling Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)